[
    [
        {
            "time": "",
            "original_text": "厦门万泰生物研发的国产宫颈癌疫苗获批，填补市场缺口",
            "features": {
                "keywords": [
                    "万泰生物",
                    "国产",
                    "宫颈癌疫苗",
                    "获批",
                    "市场缺口"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "万泰生物IPO过会 销售费占营收比重较高受发审委关注",
            "features": {
                "keywords": [
                    "万泰生物",
                    "IPO",
                    "过会",
                    "销售费",
                    "营收",
                    "发审委"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "329元/支！首个国产宫颈癌疫苗上市，14岁以下接种2针 研发企业实控人为农夫山泉老板",
            "features": {
                "keywords": [
                    "国产",
                    "宫颈癌疫苗",
                    "上市",
                    "329元/支",
                    "14岁以下",
                    "农夫山泉",
                    "老板"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]